HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance [0.03%]
缺氧诱导的肺癌细胞耐药性的逆转及低氧预处理对吉西他滨联合顺铂疗效的影响
Haojie Jiang,Shunhui Cai,Xiaojun Zhang et al.
Haojie Jiang et al.
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved survival, acquired resistance mediated by tumor hypoxia a...
Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms [0.03%]
芳基哌嗪衍生物NAF19抑制前列腺癌及其分子机制研究
Hua Jiang,Mingzhen Xu,Songsong Jiang et al.
Hua Jiang et al.
Background and objectives: Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate cancer. However, most patients relapse within 18-24 months, progressing to castration-resistant prostate ca...
Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations [0.03%]
维洛扎辛药理的更新：实验确定了在治疗相关浓度下与去甲肾上腺素转运体结合和与血清素5-ht2c、5-ht2b和5-ht7受体结合
Jennie Garcia-Olivares,Brittney Yegla,Jennifer Koch et al.
Jennie Garcia-Olivares et al.
Background and objectives: Viloxazine, which has been used to treat depression and attention-deficit/hyperactivity disorder (ADHD), has been termed a moderate-affinity, selective norepinephrine reuptake inhibitor based on...
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies [0.03%]
肾功能或肝功能损害对Iclepertin（BI 425809）药代动力学影响：两项I期开放标签、非随机对照单次给药平行设计研究结果
HeeJae Choi,Shilpa Madari,Elmar Daalman et al.
HeeJae Choi et al.
Background and objectives: Iclepertin, a selective GlyT1 inhibitor undergoes metabolism mainly via hepatic CYP3A4, with only a small fraction undergoing urinary excretion. Patients with kidney or liver problems can have r...
Clinical Trial
Drugs in R&D. 2026 Mar;26(1):83-100. DOI:10.1007/s40268-026-00537-w 2026
Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema [0.03%]
Hereditary血管性水肿患者的兰达木单抗每2周治疗效果与加拉西姆单抗非常相似
Irmgard Andresen,Natalie Khutoryansky,Sarah L Feeny et al.
Irmgard Andresen et al.
Pharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions [0.03%]
piracetam片剂在中国健康受试者中的药代动力学及生物等效性评价：随机、开放、单一剂量、两周期交叉空腹及餐后试验
Hegui Yan,Ming Zhou,Zhixiang Pan et al.
Hegui Yan et al.
Background: Piracetam, a nootropic drug, is widely used for treating cognitive impairments. However, pharmacokinetic and bioequivalence data for piracetam formulations in the Chinese population are limited. This study was...
Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam [0.03%]
布洛昔康控制释放多单元片剂的开发与评价
Yang Liu,Qiong-Zhi Shi,Yanchen Wang et al.
Yang Liu et al.
Background and objective: Lornoxicam (LOX) is a nonsteroidal anti-inflammatory drug used for pain management but requires frequent dosing due to its short half-life. This study aimed to develop a biphasic-release multiple...
Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier [0.03%]
克服生物屏障的先进药物递送策略：肿瘤微环境和血脑屏障
Yicong Lei,Tingyu Xiao,Xin Hu et al.
Yicong Lei et al.
Therapeutic efficacy for malignancies and neurological disorders is fundamentally restricted by biological barriers, particularly the complex tumor microenvironment (TME) and selective blood-brain barrier (BBB). This review analyzes advance...
Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile [0.03%]
AHT-102的药代动力学、抗肿瘤疗效、组织分布和安全性研究
Huilun Chu,Guili Xu,Yunlong Liu et al.
Huilun Chu et al.
Background and objectives: Claudin18.2 (CLDN18.2) is a promising therapeutic target overexpressed in various tumor tissues. While CD3-engaging bispecific antibodies show great potential, their clinical application is ofte...